Filtered By:
Drug: Hydroxychloroquine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 29 results found since Jan 2013.

Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population ‐based retrospective cohort study
ConclusionsAt a dosage of > 0.5 defined daily dose, short‐term methotrexate might decrease ischemic stroke risk in RA patients, while hydroxychloroquine and sulfasalazine were neutral.
Source: APLAR Journal of Rheumatology - January 1, 2018 Category: Rheumatology Authors: Hong ‐Wei Tam, Chyong‐Mei Chen, Pui‐Ying Leong, Chao‐Hsi Chen, Yuan‐Chao Li, Yu‐Hsun Wang, Li‐Chi Lin, Jeng‐Yuan Chiou, James Cheng‐Chung Wei Tags: Original Article Source Type: research

Antiphospholipid Syndrome-Associated Crescendo Stroke Events Treated with Rituximab (P4.351)
Discussion APS is an autoimmune condition associated with persistent antiphospholipid antibodies, characterised by thrombosis and pregnancy morbidity [1].Regarding APS and stroke the optimal antithrombotic agent, intensity of anticoagulation, and duration of treatment remains controversial[2]. Analysis of the APASS subgroup in the WARS study found aspirin and warfarin to be equally effective agents for secondary stroke prevention [2]. The majority of panel members at the International Congress on Antiphospholipid Antibodies recommended warfarin or combination aspirin and warfarin for patients with definite APS and arterial...
Source: Neurology - April 3, 2016 Category: Neurology Authors: O' Connor, A., Murphy, G., Cronin, S. Tags: Cerebrovascular Case Reports Source Type: research

Hydroxychloroquine exposure reduces the risk of cardiovasular disease events in patients with hypertension or diabetes mellitus
CONCLUSIONS: HCQ has protective effect on CVD events, including both AMI and ischaemic stroke in the patients with traditional risk factors. The protective effect of HCQ on CVD events is prominent in older patients.PMID:37246776 | DOI:10.55563/clinexprheumatol/y7psev
Source: Clinical and Experimental Rheumatology - May 29, 2023 Category: Rheumatology Authors: Chun-Hsiung Chen Hung-An Chen Hsien-Tzung Liao Chen-Hung Chen Source Type: research

Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study
ConclusionCutaneous vasculitis and antiphospholipid antibodies (aPLs) are associated with an increased risk of ICVD, while HCQ therapy may provide protection against ICVD in SLE. The ICVD in younger lupus patients is associated with complement-mediated inflammation and poorer outcome, and require immunosuppressive therapy, whereas the ICVD in elderly patients are characterized by moderate ICAS and carotid atherosclerotic plaques.
Source: Frontiers in Immunology - September 27, 2022 Category: Allergy & Immunology Source Type: research

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients Preventive Cardiology
Conclusion In this hypothesis-generating study, hydroxychloroquine use was associated with a 72% decrease in the risk of incident CVD in RA patients. If these preliminary results are confirmed in larger studies, our findings may be used as a rationale for a randomized study of hydroxychloroquine use for primary prevention of CVD in RA or nonrheumatic high-risk patients.
Source: JAHA:Journal of the American Heart Association - January 4, 2016 Category: Cardiology Authors: Sharma, T. S., Wasko, M. C. M., Tang, X., Vedamurthy, D., Yan, X., Cote, J., Bili, A. Tags: Cardiovascular Disease, Primary Prevention Preventive Cardiology Source Type: research

Recurrent cerebellar infarction associated with hereditary heterozygous protein C deficiency in a 35-year-old woman: A case report and genetic study on the pedigree.
In conclusion, the clinical manifestations of hereditary PROC deficiency may vary between individuals. The heterozygous mutation locus c.565C>T on the PROC gene is associated with thrombophilia. Awareness of the association between natural anticoagulants and thrombophilia may promote the prevention and therapy of stroke. PMID: 30210609 [PubMed]
Source: Experimental and Therapeutic Medicine - September 14, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Childhood-onset systemic polyarteritis nodosa and systemic lupus erythematosus: an overlap syndrome?
In conclusion, we described herein a possible overlap syndrome of two autoimmune diseases, where childhood-onset systemic polyarteritis nodosa occurred five years before the childhood-onset systemic lupus erythematosus diagnosis.
Source: Revista Brasileira de Reumatologia - July 13, 2015 Category: Rheumatology Source Type: research

Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications
AbstractThe SARS-CoV-2 virus that is the cause of coronavirus disease 2019 (COVID-19) affects not only peripheral organs such as the lungs and blood vessels, but also the central nervous system (CNS) —as seen by effects on smell, taste, seizures, stroke, neuropathological findings and possibly, loss of control of respiration resulting in silent hypoxemia. COVID-19 induces an inflammatory response and, in severe cases, a cytokine storm that can damage the CNS. Antimalarials have unique properti es that distinguish them from other anti-inflammatory drugs. (A) They are very lipophilic, which enhances their ability to cross ...
Source: Molecular Neurobiology - November 27, 2020 Category: Neurology Source Type: research

Common drug for Sjögren’s does not help symptoms
Hydroxychloroquine didn’t reduce dryness, pain or fatigue more than placebo Related items from OnMedicaNewer RA drugs no better than old in keeping patients at workThyroid patients need better monitoringDrugs regulators “put profits before patients”Lupus anticoagulant greatly raises stroke risk
Source: OnMedica Latest News - July 17, 2014 Category: UK Health Source Type: news